CSSI - Costas, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 1:40PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close0.0122
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0122 - 0.0122
52 Week Range0.0100 - 0.1600
Avg. Volume6,018
Market Cap174,283
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.0780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies to License the FirstEver Nanotechnology Vitamin A (Retinol) Based Crystalline Eye Drop

    GUADALAJARA, Mexico, Nov. 14, 2019 (GLOBE NEWSWIRE) -- vía OTC PR WIRE – Costas, Inc. (CSSI) DBA/Atlas Nanotech, (the “Company”) is currently in discussions to license their proprietary nanotechnology vitamin a (retinol) based crystalline eye drops known under the trade name “NANO CLEAR A”, to the leading eye drop manufactures, by licensing Nano Clear A to existing top tier eye drop manufactures it will allow the product to be widely used at a rapid pace. Atlas Nanotech’s business model is to develop and patent unique nanotechnology products. The Company’s scientific team is confident in its ability to license existing products and continue to develop additional nanotechnology products that the company will license to some of the world’s leading biotechnology, pharmaceutical and consumer products manufacturers.

  • Atlas Nanotech Announces the Successful Development of the First Ever ‘Over The Counter’ Vitamin ‘A’ (Retinol) Eye-Drops

    Atlas Nanotech Announces the Successful Development of the First Ever ‘Over The Counter’ Vitamin ‘A’ (Retinol) Eye-Drops

    GUADALAJARA, México, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Costas Inc. (CSSI) DBA Atlas Nanotech adds another unique nanotechnology medical product to its portfolio. The product to be sold under the trade name “NANO CLEAR A” will compete with products in the treatment of dry eye disease, a $1.8-billion market in the U.S. The development represents the culmination of research initiated by Dr. Aldo Oregon Miranda, an ophthalmologist surgeon and member of the scientific advisory board of Atlas Nanotech, in collaboration with Professor David De La Mora, Atlas’ chairman.

  • GlobeNewswire

    Atlas Nanotech Opens First Revenue Stream

    GUADALAJARA, Mexico, July 31, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.), DBA Atlas Nanotech, today memorialized an agreement with Laboratorios Gem S.A. de C.V. of Mexico City gemlabs.mx. The contract calls for Atlas to sell stabilized and functionalized silver nanoparticles to Gem Labs for use in the manufacture of one of Gem Labs proprietary products. The contract is understood as a first act of trade between the parties and goes on to define initial terms of a licensing agreement for the use and exploitation of Nanogasa (nanogasa.com), a patented development of Atlas Nanotech.

  • GlobeNewswire

    Atlas Nanotech of Guadalajara to begin alliance with European Nano Medical S.R.O.

    GUADALAJARA, Mexico, June 27, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.) DBA Atlas Nanotech has entered an accord with Nano Medical S.R.O. of the Czech Republic. Atlas has successfully completed the submission of documentation and payment for two unique nanotechnology products through the Mexican regulator COFEPRIS. Initially, Atlas plans to distribute Nano Medical S.R.O.’s products in Mexico and, eventually, throughout Latin America, while Nano Medical S.R.O will distribute Atlas Nanotech’s products in Europe.

  • GlobeNewswire

    COSTAS Inc. (CSSI) Acquires Medical Nanotechnology Company, Appoints New Management and Board Members

    LAS VEGAS, June 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – COSTAS,Inc.  (CSSI), announces its acquisition of Atlas Nanotech (formerly known as Nano Creaciones SAPI de CV) in an all-stock transaction that marks the Company’s entrance into the multi-billion-dollar global nanomedicine marketplace. The terms of the share exchange agreement include the appointment of new managing officers and a new board of directors, the resignation of COSTA’s current officers and board of directors and the retirement of 12,660,000 shares. The principles of Atlas are receiving 25,000,000 shares of CSSI subject to a lock-up agreement with staggered release of shares over a 2-year period.